View Older Stories View More Recent Stories

Apr 14, 2025 06:59AM Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
Apr 12, 2025 11:45PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
Apr 11, 2025 05:26PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
Apr 9, 2025 03:06PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
Apr 7, 2025 06:59AM Viatris Inc (VTRS) Issues Statement on Nationwide Settlement to Resolve Opioid-Related Claims
Apr 7, 2025 06:59AM Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
Apr 6, 2025 02:32PM ROSEN, A LEADING NATIONAL FIRM, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Apr 5, 2025 09:22AM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Mar 30, 2025 03:15PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Mar 28, 2025 03:08PM ROSEN, A LEADING LAW FIRM, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Mar 28, 2025 06:59AM Viatris to Report First Quarter 2025 Financial Results on May 8, 2025
Mar 26, 2025 08:23PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Mar 17, 2025 04:49PM ROSEN, A TOP RANKED LAW FIRM, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Mar 5, 2025 04:30PM Viatris to Present at the Barclays 27th Annual Global Healthcare Conference
Feb 27, 2025 07:05PM Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
Feb 27, 2025 06:30AM Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend
Jan 7, 2025 06:59AM Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 18, 2024 06:59AM Viatris Inc (VTRS) Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
Dec 18, 2024 06:59AM Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
Nov 7, 2024 06:59AM Viatris Reports Third Quarter Financial Results for 2024
Nov 5, 2024 06:59AM Viatris Announces Third Quarter 2024 Dividend
Oct 29, 2024 12:00PM Viatris Named to Forbes' World's Top Companies for Women 2024 List
Oct 29, 2024 09:00AM Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference
Oct 16, 2024 04:35PM Lexicon Pharma (LXRX) Announces Exclusive Licensing Agreement With Viatris (VTRS) for Sotagliflozin in All Markets Outside of the U.S. and Europe
Oct 16, 2024 04:35PM Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
Oct 16, 2024 04:34PM Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Oct 9, 2024 06:59AM Viatris Inc (VTRS) Reports Positive Top-line Results from Phase 3 Study of EFFEXOR in Japanese Adults with Generalized Anxiety Disorder (GAD)
Oct 9, 2024 06:59AM Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
Oct 8, 2024 03:40PM Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Oct 8, 2024 11:00AM Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Sep 16, 2024 04:30PM Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
Aug 23, 2024 06:59AM Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Aug 8, 2024 06:59AM Viatris Reports Second Quarter Financial Results for 2024
Aug 6, 2024 06:59AM Viatris Announces Second Quarter 2024 Dividend
Jul 3, 2024 08:31AM Viatris Inc (VTRS) Completes All Previously Announced Divestitures
Jul 3, 2024 08:30AM Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
Jul 2, 2024 07:30AM Viatris Inc (VTRS) : U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Jul 2, 2024 07:30AM U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Jun 25, 2024 05:25PM Viatris Named to TIME’s World’s Most Sustainable Companies 2024 List
Jun 25, 2024 11:00AM Viatris Named to TIME's World's Most Sustainable Companies 2024 List
Jun 7, 2024 06:59AM Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
Jun 4, 2024 06:59AM Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 3, 2024 06:59AM Viatris Inc (VTRS) Appoints Rogerio Vivaldi Coelho to its Board
Jun 3, 2024 06:59AM Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
May 31, 2024 06:59AM Viatris to Participate in the Jeffries Global Healthcare Conference
May 21, 2024 06:30PM Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale
May 21, 2024 06:59AM Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale
May 9, 2024 06:59AM Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
May 2, 2024 05:00PM Viatris to Participate in the BofA Securities 2024 Health Care Conference
May 1, 2024 06:30PM Viatris Expands Its Wellbeing Program With the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
View More Recent Stories View Older Stories